FORT WASHINGTON, Pa., Aug. 6, 2018 /CNW/ -- Today, JNCCN—Journal of the National Comprehensive Cancer Network introduced new associate editors, who reflect the journal's growing focus on original research designed to improve the quality of cancer care delivery, worldwide. The expanding focus on original research is led by Editor-in-Chief Margaret Tempero, MD, Professor of Medicine and Director of the UCSF Pancreas Center at UCSF Helen Diller Family Comprehensive Cancer Center. This vision has resulted in an all-time high impact factor for the journal. According to InCites Journal Citation Report data from Clarivate Analytics, articles from JNCCN were cited 5,143 times in 2017, resulting in an impact factor of 6.471 for the year, which places it in the top quartile for all oncology journals. This upward trajectory is also illustrated by rising readership rates in print, a half-million jump in page views online, and research submission rates increasing 500% over the past four years.
"Our greater focus on original research helps us build on the strength of the NCCN Guidelines we publish, and furthers NCCN's mission to improve the quality, effectiveness, and efficiency of care so that patients can live better lives," said Dr. Tempero. "JNCCN is a key source for new information about health services, outcomes, comparative effectiveness, and quality improvement. The studies we publish are changing the way people with cancer receive treatment by drawing attention to where we fall short and highlighting how we can do better."
In order to accommodate continuous growth, JNCCN recently restructured the make-up of the executive editorial board. After an extensive national search, the journal invited eight accomplished health services researchers from various NCCN Member Institutions to help oversee content. That group now includes:
Every issue of JNCCN also includes the publication of a recently updated edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
"The NCCN Guidelines provide the foundation which all of our work is built on," explained Robert W. Carlson, MD, Chief Executive Officer, NCCN. "JNCCN is one of the ways we share the latest updates in cancer care standards from those guidelines. The journal also provides an essential platform for disseminating the kind of high-quality research that leads to people with cancer receiving better care."
JNCCN publishes 13 issues every year, with select content available for free online at JNCCN.org for three months after publication. NCCN Guidelines Panel Chairs serve as members of JNCCN's Guidelines Editorial Board to provide additional oversight, topic suggestions, and feedback on editorial decisions.
AboutJNCCN—Journal of the National Comprehensive Cancer Network More than 25,000 oncologists and other cancer care professionals across the United States read JNCCN—Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information about best clinical practices, health services research, and translational medicine. JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), review articles elaborating on guidelines recommendations, health services research, and case reports highlighting molecular insights in patient care. JNCCN is published by Harborside Press. Visit JNCCN.org. To inquire if you are eligible for a FREE subscription to JNCCN, visit http://www.nccn.org/jnccn/subscribe.asp. Follow JNCCN on Twitter @JNCCN.
About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope National Medical Center, Duarte, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Rogel Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.